Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients
- PMID: 7579369
Late infections after allogeneic bone marrow transplantations: comparison of incidence in related and unrelated donor transplant recipients
Abstract
Infectious complications are a major cause of morbidity and mortality after allogeneic bone marrow transplantation (BMT). We have evaluated the incidence of late infections (beyond day +50) in recipients of related (RD) and unrelated donor (URD) allogeneic BMT, factors associated with increased risks of infection, and the impact of the late infections on survival. Between 1989 and 1991, 249 patients received an RD (n = 151) or URD (n = 98) allogeneic BMT at the University of Minnesota and all late infections were investigated. Three hundred sixty-seven late infectious events developed in 162 patients between 50 days and 2 years after BMT. The incidence of any late infection was greater in URD versus RD recipients (84.7% v 68.2%, respectively; P = .009). In multivariate analysis, advanced graft-versus-host disease (GVHD) was significantly associated with late infections. The effect of GVHD was apparent only in RD recipients (relative risk [RR], 2.29; P = .003), whereas URD recipients, with or without GVHD, had more late infections compared with RD recipients without GVHD. Multivariate analysis showed that late posttransplantation infections were the dominant independent factor associated with increased nonrelapse mortality (RR, 5.5; P = .0001), resulting in improved 3-year survival for RD versus URD recipients (49.9% +/- 8% v 34.4% +/- 10%; P = .004). In this study, we observed that late infections are more frequent in URD recipients, resulting in substantially higher nonrelapse mortality. This prolonged period of increased infectious risk in URD recipients suggests the need for aggressive surveillance and therapy of late infections and perhaps prolonged antibiotic prophylaxis for all URD BMT recipients.
Similar articles
-
Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.Blood. 2002 Mar 15;99(6):1971-7. doi: 10.1182/blood.v99.6.1971. Blood. 2002. PMID: 11877268
-
Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia.Cancer. 2017 Sep 1;123(17):3346-3355. doi: 10.1002/cncr.30737. Epub 2017 Apr 27. Cancer. 2017. PMID: 28452054 Free PMC article.
-
Relapse after non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: early transplantation, use of an unrelated donor, and chronic graft-versus-host disease are protective.Blood. 1996 Jul 15;88(2):714-20. Blood. 1996. PMID: 8695820
-
Acute graft-versus-host disease and the risks for idiopathic pneumonia after marrow transplantation for severe aplastic anemia.Bone Marrow Transplant. 1993 Sep;12(3):225-31. Bone Marrow Transplant. 1993. PMID: 8241981 Review.
-
Unrelated donor bone marrow transplantation for hematological malignancies-current status.Leuk Lymphoma. 1996 Oct;23(3-4):221-6. doi: 10.3109/10428199609054824. Leuk Lymphoma. 1996. PMID: 9031102 Review.
Cited by
-
Rabbit antithymocyte globulin (thymoglobulin) impairs the thymic output of both conventional and regulatory CD4+ T cells after allogeneic hematopoietic stem cell transplantation in adult patients.Haematologica. 2013 Jan;98(1):23-30. doi: 10.3324/haematol.2012.067611. Epub 2012 Jul 16. Haematologica. 2013. PMID: 22801968 Free PMC article.
-
Bone marrow transplantation using unrelated donors for haematological malignancies.Med Oncol. 1997 Mar;14(1):11-22. doi: 10.1007/BF02990940. Med Oncol. 1997. PMID: 9232606 Review.
-
Reconstitution of the immune system after hematopoietic stem cell transplantation in humans.Semin Immunopathol. 2008 Dec;30(4):425-37. doi: 10.1007/s00281-008-0132-5. Epub 2008 Oct 24. Semin Immunopathol. 2008. PMID: 18949477 Review.
-
Association between Antiviral Prophylaxis and Cytomegalovirus and Epstein-Barr Virus DNAemia in Pediatric Recipients of Allogeneic Hematopoietic Stem Cell Transplant.Vaccines (Basel). 2021 Jun 7;9(6):610. doi: 10.3390/vaccines9060610. Vaccines (Basel). 2021. PMID: 34200239 Free PMC article.
-
Post-transplant adoptive T-cell immunotherapy.Best Pract Res Clin Haematol. 2008 Sep;21(3):503-19. doi: 10.1016/j.beha.2008.07.001. Best Pract Res Clin Haematol. 2008. PMID: 18790452 Free PMC article. Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous